Failure of selenium-ace to improve osteoarthritis.
Selenium-ACE, a formulation containing the trace element selenium with three vitamins, is widely promoted for the treatment of arthritis. A controlled double-blind trial of Selenium-ACE in osteoarthritis failed to demonstrate any significant efficacy for the compound over placebo at 3 or 6 months though there was a non-significant trend to improvement in some clinical parameters in both groups. Side-effects were more frequently seen in the placebo group.
Hill
J
J
Clinical Pharmacology Unit (Rheumatism Research), Royal Bath Hospital, Harrogate, UK.
Bird
H A
HA
D000328:Adult; D000368:Aged; D001205:Ascorbic Acid / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009068:Movement; D010003:Osteoarthritis / Q000188:drug therapy* / Q000503:physiopathology; D010146:Pain; D011897:Random Allocation; D012643:Selenium / Q000008:administration & dosage*; D013997:Time Factors; D014801:Vitamin A / Q000008:administration & dosage*; D014810:Vitamin E / Q000008:administration & dosage*
D004338:Drug Combinations; D014801:Vitamin A; D014810:Vitamin E; D012643:Selenium; D001205:Ascorbic Acid